Episode 54
Biotech Hangout
00:00
Kirt XT for DLBCL Hits on Survival
The FGF21 did show a strong fibrosis benefit in NASH, which I would say supports the strong results also out of a carot. Kite or Giliad's Yeskarta for DLBCL hit on survival against standard of carahidose chemo and stem cell transplant. CAR XT was actually an originally pure tech innovation. Daphne maybe can give us a quick history of that product. And I think you also monetized some of the CAR XT royalty in a royalty pharma deal.
Transcript
Play full episode
